Abstract: Bone and soft tissue tumors are a group of clinically rare malignancies with abundant subtypes. These tumors, particularly sarcomatous lesions, are challenging to diagnose and treatment because of their aggressiveness and poor prognosis. In recent years, next-generation sequencing (NGS) has been widely used for molecular diagnosis, targeted gene screening, and epigenetic analysis of tumors with the development of molecular detection technology, which improves the diagnosis and treatment of bone and soft tissue tumors to some extent. Currently, there are still many doubts about the application of NGS for bone and soft tissue tumors. Based on available medical evidence and expert opinions, the sarcoma committee of the China Anti-Cancer Association Committee of Sarcoma issued a consensus regarding the application of NGS for bone and soft tissues with respect to detection using NGS, clinical application, and laboratory quality control. The consensus aimed to standardize the utility of NGS in detecting bone and soft tissue tumors and facilitate clinical diagnosis and treatment of these tumors for the benefit of patients.